Glaucoma patients in the United States also gained a diagnostic tool with the FDA approval of an IOP self-monitoring device (Icare HOME tonometer, Icare USA). The device, which has been available in Europe since 2014, is designed for use by patients. It performs automatic OD/OS recognition, uses green and red lights as guidance for positioning, requires no drops, and involves no puff of air.
The device allows patients to monitor their IOP throughout the day and could make physicians aware of any dangerous spikes, according to the company.
It is not yet clear how well patients can use the device, or what use clinicians can make of the data it provides, Dr. Iwach said.
“One of the questions is going to be when is the data going to affect what we do, especially if it requires an active step from the patient.”
Implandata’s Eyemate, by contrast, is implanted in the eye, allowing passive monitoring of IOP. In May, the device received CE Mark approval and is available for commercial use within Europe. That type of monitoring “may be appropriate, but we have to determine when it’s appropriate,” Dr. Iwach said.